EMI (Encore Medical) Common Stock: $0.06 Mil (As of Dec. 2025)


What is Encore Medical Common Stock?

Encore Medical EMI Common Stock is $0.06 Mil as of Dec. 2025.

Encore Medical's quarterly common stock stayed the same from Jun. 2025 ($0.06 Mil) to Sep. 2025 ($0.06 Mil) and stayed the same from Sep. 2025 ($0.06 Mil) to Dec. 2025 ($0.06 Mil).

Encore Medical's annual common stock increased from Dec. 2023 ($0.06 Mil) to Dec. 2024 ($0.06 Mil) and increased from Dec. 2024 ($0.06 Mil) to Dec. 2025 ($0.06 Mil).

Encore Medical Common Stock Historical Data

* Premium members only.

The historical data trend for Encore Medical's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Encore Medical Common Stock Chart

Encore Medical Annual Data
Trend Dec23 Dec24 Dec25
Common Stock
0.06 0.06 0.06

Encore Medical Quarterly Data
Dec23 Sep24 Dec24 Jun25 Sep25 Dec25
Common Stock Get a 7-Day Free Trial 0.00 0.06 0.06 0.06 0.06

Encore Medical Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of $0.06 Mil mean?
Encore Medical (EMI) has a Common Stock of $0.06 Mil as of Dec. 2025. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Encore Medical and its competitors.
Is Encore Medical's Common Stock too high?
Encore Medical's current Common Stock is $0.06 Mil.
How does Encore Medical's Common Stock compare to ?
Encore Medical's Common Stock of $0.06 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Medical Devices & Instruments company?
A good Common Stock depends on the Medical Devices & Instruments industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Encore Medical and its competitors. Encore Medical's current Common Stock is $0.06 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Encore Medical stock overvalued right now?
Encore Medical (EMI) has a current Common Stock of $0.06 Mil. The current Common Stock is $0.06 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Encore Medical (EMI), the current Common Stock is $0.06 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Encore Medical Business Description

Comparable Companies
Address 2975 Lone Oak Drive, Suite 140, Eagan, MN, USA, 55121
Encore Medical Inc develops, manufactures, and markets septal occlusion devices for the repair of certain cardiac defects. Its products have been implanted in approximately 35,000 patients outside the United States. Its closure device is designed to correct a cardiac defect, generally diagnosed in adulthood, known as a patent foramen ovale (PFO). The company also currently market and sell septal occlusion devices for the transcatheter closure of atrial septal defects (ASD).